Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Estrogen sulfamate derivatives were the first irreversible active-site-directed inhibitors of steroid sulfatase (STS), an emerging drug target for endocrine therapy of hormone dependent diseases that catalyzes inter alia the hydrolysis of estrone sulfate to estrone. In recent years this has stimulated clinical investigation of the estradiol derivative both as an oral prodrug and its currently ongoing exploration in endometriosis. 2-Substituted steroid sulfamate derivatives show considerable potential as multi-targeting agents for hormone-independent disease, but are also potent STS inhibitors. The steroidal template has spawned nonsteroidal STS inhibitors one of which, Irosustat, has been evaluated clinically in breast cancer, endometrial cancer and prostate cancer and there is potential for innovative dual-targeting approaches. This review surveys the role of estrogen sulfamates, their analogues and current status.

Original publication

DOI

10.1016/j.jsbmb.2015.03.012

Type

Journal article

Journal

J Steroid Biochem Mol Biol

Publication Date

09/2015

Volume

153

Pages

160 - 169

Keywords

Cancer, Endocrine Therapy, Inhibitor, Sulfamates, Sulfatase, Synthesis, Animals, Coumarins, Enzyme Inhibitors, Estradiol, Estrogens, Estrone, Humans, Models, Molecular, Steryl-Sulfatase, Sulfonamides